Clinical trials: multiple sclerosis
Multiple Sclerosis
HFS (High-Fiber Supplement) in MS (Multiple Sclerosis)
Multiple sclerosis (MS) is an autoimmune disease directed against the Central Nervous System (CNS). Recent studies have indicated that changes in the gut microbiota are associated with disease initiation and progression.
- Trial name
- NCT04574024
- Testing
- NBT-NM108
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Suhayl Dhib-Jalbut, MD
Relapsing Multiple Sclerosis
Study of Evobrutinib in Participants With RMS (evolutionRMS 2)
The study is to evaluate the efficacy and safety of evobrutinib administered orally twice daily versus Teriflunomide (Aubagio®), administered orally once daily in participants with Relapsing Multiple Sclerosis (RMS).
- Trial name
- NCT04338061
- Testing
- Teriflunomide, Evobrutinib
- Where
- 278 sites in United States, Belarus and 30 more
- Volunteers
- 1,166 people
- Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Spasticity, Multiple Sclerosis
Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis
This is a multicenter, randomized (1:1:1), double-blind, active and placebo controlled, parallel group study to evaluate safety, tolerability and efficacy of oral arbaclofen in MS patients with spasticity.
- Trial name
- NCT01743651
- Testing
- arbaclofen, baclofen
- Where
- 48 sites in United States, Russia and 1 more
- Volunteers
- 353 people
- Sponsor
- RVL Pharmaceuticals, Inc.
Multiple Sclerosis
Analyze the Myelin-TRAP as Diagnostic Tool in Multiple Sclerosis
The objective of this project is to characterize the response TRAP positive patients with Multiple Sclerosis (MS) and to evaluate the sensitivity and specificity of the method in order to develop a second time as a diagnostic…
- Trial name
- TRAP-Myéline (NCT01723631)
- Testing
- Trap Myelin Test
- Where
- 11 sites in France
- Volunteers
- 189 people, healthy volunteers welcome
- Sponsor
- Nantes University Hospital
Falls Prevention
Vibration Training for Preventing Falls in Healthy Population and Multiple Sclerosis
This study is to investigate the effects of controlled whole-body vibration training on reducing the likelihood of falls among healthy population and people with multiple sclerosis.
- Trial name
- NCT02694666
- Testing
- Controlled whole-body vibration training
- Where
- United States
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Georgia State University
Multiple Sclerosis
Effects of Qigong Therapy in MS Patients
Chinese medical exercises (Qigong) are part of traditional Chinese medicine and martial arts, consisting of exercise sequences originating from China.
- Trial name
- NCT07473180
- Testing
- Conventional rehabilitation therapy, Qi gong Baduanjin Exercises
- Where
- Turkey (Türkiye)
- Volunteers
- 36 people
- Sponsor
- Baskent University
Healthy Volunteers
Safety Study of GNbAC1 Monoclonal Antibody in Healthy Male Volunteers
In this clinical study, the safety and tolerability of GNbAC1 as a treatment for MS patients will be evaluated in healthy male volunteers.
- Trial name
- NCT02452996
- Testing
- GNbAC1
- Where
- Germany
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- GeNeuro Innovation SAS
Multiple Sclerosis
Mindfulness-based Stress Reduction for Multiple Sclerosis
The primary purpose of this study is to assess the feasibility of mindfulness-based stress reduction (MBSR) for adults with any type of multiple sclerosis.
- Trial name
- NCT02340754
- Testing
- Mindfulness-based Stress Reduction, MS Education Control
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- National University of Natural Medicine
Multiple Sclerosis
Effectiveness of a Digital Health Application for Multiple Sclerosis (Levidex)
The trial aims to evaluate the effectiveness of a novel digital health application (levidex), which was designed to increase quality of life in persons with multiple sclerosis (MS).
- Trial name
- LAMONT (NCT06090305)
- Testing
- levidex, Control, treatment as usual (TAU)
- Where
- Germany
- Volunteers
- 470 people
- Sponsor
- Gaia AG
Multiple Sclerosis
Early Symptoms in Multiple Sclerosis: an Investigation Using fMRI and Gait Analysis to Develop Personalized Balance Training for People With Low Disability
Background Many people with Multiple Sclerosis (MS) experience a hidden yet clinically significant symptom: impaired balance or a persistent feeling of instability, even during the early stages of the disease (Martin et al.…
- Trial name
- EMS_Rehab (NCT07805733)
- Testing
- Vestibular Physical Therapy
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- LIFE - Research and Care Institute - Santa Lucia IRCCS
Pain, Multiple Sclerosis
A Study to Evaluate the Effects of Cannabis Based Medicine in Patients With Pain of Neurological Origin
To investigate the ability of a cannabis based medicine extract to relieve chronic refractory pain of neurological origin.
- Trial name
- NCT01606176
- Testing
- GW-1000-02
- Where
- United Kingdom
- Volunteers
- 70 people
- Sponsor
- Jazz Pharmaceuticals
Tuberous Sclerosis, Subependymal Giant Cell Astrocytoma
Everolimus (RAD001) Therapy of Giant Cell Astrocytoma in Patients With Tuberous Sclerosis Complex
The purpose of the study is to evaluate the safety and potential side effects of everolimus (an experimental drug) on a person with Tuberous Sclerosis Complex who also has been diagnosed with a brain tumor (astrocytoma) The…
- Trial name
- NCT00411619
- Testing
- Everolimus
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Cognition Disorders, Multiple Sclerosis
A Study of C105 on Cognitive Dysfunction in Persons With Multiple Sclerosis
The purpose of this study is to determine the safety and efficacy of C105 in treating the cognitive deficits that can occur due to multiple sclerosis.
- Trial name
- NCT00529581
- Testing
- C105
- Where
- 30 sites in United States
- Volunteers
- 150 people
- Sponsor
- Cognition Pharmaceuticals, LLC
Multiple Sclerosis, Relapsing-Remitting
A 12 -Month, Open-label, Multi-center Study to Explore the Health Outcomes of FTY720
The study will assess the patients' satisfaction of treatment after 12 months treatment with fingolimod It also will assess the tolerability profile of fingolimod in a small population.
- Trial name
- NCT01578330
- Testing
- Fingolimod
- Where
- 11 sites in Turkey (Türkiye)
- Volunteers
- 42 people
- Sponsor
- Novartis Pharmaceuticals
Relapsing-Remitting Multiple Sclerosis
Effects of Electromechanical Gait Trainer in Patients With Multiple Sclerosis
Multiple Sclerosis is a very disabling disorder in young adult patients leading to an important limitation in daily life activities and social participation.
- Trial name
- NCT01564511
- Testing
- Gait trainer treatment, Conventional treatment
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Universita di Verona
Multiple Sclerosis
MS-Related Disability Worsening and Thalamic Volume Loss
PENTAGON is an observational, non-interventional, multicenter, prospective cohort study conducted at approximately 20 neurology centers and affiliated radiology centers across Germany.
- Trial name
- PENTAGON (NCT07753928)
- Testing
- Disease-Modifying Therapies (DMTs)
- Where
- 2 sites in Germany
- Volunteers
- 2,400 people
- Sponsor
- Jung Diagnostics GmbH
Relapsing-remitting Multiple Sclerosis
A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis
This is a double-blind, randomized, active-controlled, parallel group, Phase 1/3 study to compare efficacy, PK, PD and overall safety of CT-P53 with Ocrevus in patients with Relapsing-remitting Multiple Sclerosis.
- Trial name
- NCT05906992
- Testing
- CT-P53, US-Ocrevus, EU-Ocrevus
- Where
- Poland
- Volunteers
- 512 people
- Sponsor
- Celltrion
Multiple Sclerosis
FMT for MS Patients
This is a placebo-controlled, double-blinded, randomized trial design, whereby all patients are eligible to start an injectable therapy, and then randomized to either placebo or FMT for approximately 1 year.
- Trial name
- MS-FMT (NCT04150549)
- Testing
- Fecal Microbial Transplants
- Volunteers
- 34 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Multiple Sclerosis
Clinical Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Ponesimod in Patients With Relapsing-remitting Multiple Sclerosis
This study is an extension to the study AC-058B201 and will investigate the long-term safety, tolerability and efficacy of ponesimod in patients with relapsing-remitting multiple sclerosis.
- Trial name
- NCT01093326
- Testing
- Ponesimod 10 mg, Ponesimod 20 mg, Ponesimod 40 mg
- Where
- 71 sites in United States, Austria and 18 more
- Volunteers
- 353 people
- Sponsor
- Actelion
Multiple Sclerosis, Relapsing-Remitting
A Trial for Evaluating Both Safety and Preliminary Efficacy of a Single Infusion of Stimulated Autologous CD4+T Cells in Patients With Relapsing- Remitting Multiple Sclerosis
The purpose of this study is to assess the safety and the preliminary efficacy of a single infusion of stimulated autologous CD4+ T cells in patients with Relapsing-Remitting Multiple Sclerosis.
- Trial name
- SCLEROLYM (NCT02427776)
- Testing
- Autologous CD4+T cells stimulated and expanded ex vivo by a MOG peptide modified by the introduction of a thioreductase motif into the flanking residues of the T cell epitope
- Where
- 3 sites in Belgium
- Volunteers
- 2 people
- Sponsor
- Imcyse SA
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.